Vascular diseases

Worldwide Peripheral Artery Disease Industry to 2027 - Opportunity Analysis and Industry Forecast - ResearchAndMarkets.com

Retrieved on: 
Friday, September 4, 2020
Health, Other Health, RTT, Artery disease, Peripheral artery disease, Vascular diseases

The "Peripheral Artery Disease Market by Type, Filters, Devices and Peripheral Accessories: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peripheral Artery Disease Market by Type, Filters, Devices and Peripheral Accessories: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global peripheral artery disease market accounted for $3,524.77 million in 2019, and is expected to reach $5,715.12 million by 2027, registering a CAGR of 8.5% from 2020 to 2027.
  • Peripheral artery disease (PAD) is a disease of blood vessels located outside the brain and heart.
  • Factors such as rapid growth in geriatric population and subsequent increase in prevalence of peripheral artery diseases, along with increase in product approvals drive growth of the peripheral artery disease market.

Tactile Medical to Participate in Two Upcoming Investor Conferences in September

Retrieved on: 
Tuesday, September 1, 2020
Vascular diseases, Lymphedema, Venous insufficiency, Chronic venous insufficiency, Insufficiency

MINNEAPOLIS, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the following upcoming investor conferences:

Key Points: 
  • MINNEAPOLIS, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the following upcoming investor conferences:
    Management will participate in virtual 1x1 meetings on Thursday, September 10.
  • Management will participate in a fireside chat on Thursday, September 17 at 2:00pm Eastern Time.
  • A live audio webcast of the fireside chat will be accessible under the Events & Webcasts section of the Company's investor relations website at http://investors.tactilemedical.com .
  • Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency.

Outlook on the Brain Aneurysm Treatment Global Market to 2027 - by Type, Condition, End-user and Geography

Retrieved on: 
Wednesday, August 26, 2020
Medical specialties, Angiology, Organ systems, Neurosurgery, Vascular diseases, Cerebrovascular diseases, Aneurysm, Gross pathology, Intracranial aneurysm, Vascular surgery, Aortic aneurysm, Subarachnoid hemorrhage

Driving factors of the brain aneurysm treatment market are increasing prevalence of brain aneurysm and associated risk factors and rise in research and development activities.

Key Points: 
  • Driving factors of the brain aneurysm treatment market are increasing prevalence of brain aneurysm and associated risk factors and rise in research and development activities.
  • The growth of brain aneurysm treatment market is prominently attributed to the increasing prevalence of brain aneurysm across the globe.
  • Such massive epidemics of hypertension are likely to increase the cases of brain aneurysm, which in turn will propel the growth of brain aneurysm treatment market from 2020-2027.
  • Based on condition, the brain aneurysm treatment market is segmented into unruptured aneurysm and ruptured aneurysm.

Worldwide Brain Aneurysm Treatment Industry to 2027 - Featuring Mizuho Medical, Penumbra & Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 25, 2020
Health, Biotechnology, Medical specialties, Angiology, Organ systems, Neurosurgery, Vascular diseases, Cerebrovascular diseases, Aneurysm, Gross pathology, Intracranial aneurysm, Vascular surgery, Aortic aneurysm, Subarachnoid hemorrhage

Driving factors of the brain aneurysm treatment market are increasing prevalence of brain aneurysm and associated risk factors and rise in research and development activities.

Key Points: 
  • Driving factors of the brain aneurysm treatment market are increasing prevalence of brain aneurysm and associated risk factors and rise in research and development activities.
  • The growth of brain aneurysm treatment market is prominently attributed to the increasing prevalence of brain aneurysm across the globe.
  • Such massive epidemics of hypertension are likely to increase the cases of brain aneurysm, which in turn will propel the growth of brain aneurysm treatment market from 2020-2027.
  • Based on condition, the brain aneurysm treatment market is segmented into unruptured aneurysm and ruptured aneurysm.

Stryker launches first 64-wire cobalt chromium flow diverter in the US to treat brain aneurysms

Retrieved on: 
Monday, August 24, 2020
Vascular diseases, Software, Medical specialties, Free software, Flow diverter, Prosthetics, Neurosurgery, Aneurysm, Intracranial aneurysm, Chromium

It is the first 64-wire cobalt chromium flow diverter in the U.S. designed to re-direct blood flow and promote aneurysm healing.

Key Points: 
  • It is the first 64-wire cobalt chromium flow diverter in the U.S. designed to re-direct blood flow and promote aneurysm healing.
  • "This device builds on the success of Surpass Streamline, offering a highly optimized and easy to use flow diverter.
  • Stryker is dedicated to working with our customers to bring life-saving technologies to patients suffering from brain aneurysms."
  • Important safety information for the Surpass Evolve Flow Diverter may be accessed here: www.strykerneurovascular.com/dfu

JanOne to Host Telebriefing to Discuss Drug Candidate JAN101 for Treatment of Peripheral Artery Disease (PAD) and Potential Applications for COVID-19 Vascular Complications

Retrieved on: 
Friday, August 21, 2020
RTT, Peripheral artery disease, Artery disease, Pad, Vascular diseases

The company believes that JAN101 is a potential treatment for peripheral artery disease (PAD) and may have applications for COVID-19 vascular complications.

Key Points: 
  • The company believes that JAN101 is a potential treatment for peripheral artery disease (PAD) and may have applications for COVID-19 vascular complications.
  • Dial in Number for U.S. Callers:877-407-8293
    A replay will be available for two weeks starting on August 25, 2020 at approximately 7:15 P.M.
  • JanOne's first drug candidate, JAN101, is a patented sodium nitrite sustained release tablet formulated to treat PAD and other vascular conditions.
  • Its lead candidate JAN101 is for treating peripheral artery disease (PAD), a condition that affects over 8.5 million Americans.

Endospan Receives FDA IDE Approval to Initiate a Pivotal Study of the NEXUS™ Aortic Arch Stent Graft System

Retrieved on: 
Monday, August 17, 2020
FDA, Health, Cardiology, Medical devices, Anatomy, Angiology, Torso, Interventional radiology, Aorta, Stent, Investigational device exemption, Aortic arch, Vascular surgery, Vascular diseases, Thoracic aortic aneurysm, Aortic aneurysm

Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease received approval from FDA of an investigational device exemption, or IDE, to start the TRIOMPHE study on the NEXUS Aortic Arch Stent Graft System (hereinafter referred to as NEXUSTM).

Key Points: 
  • Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease received approval from FDA of an investigational device exemption, or IDE, to start the TRIOMPHE study on the NEXUS Aortic Arch Stent Graft System (hereinafter referred to as NEXUSTM).
  • The TRIOMPHE pivotal study will assess the NEXUSTM in some of the most challenging Aortic Arch Pathologies that we encounter.
  • Endospans NEXUSTM Aortic Arch Stent Graft System is the first endovascular off-the-shelf system with CE Mark to treat a greatly underserved group of patients diagnosed with a dilative lesion in, or near the aortic arch.
  • NEXUSTM Aortic Arch Stent Graft System is currently available for sale in Europe and is intended for investigational use only in the U.S.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200817005127/en/

Venous Skin Ulcer Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

Retrieved on: 
Thursday, August 13, 2020
Medical specialties, Medicine, Surgery, Ulcer, Clinical medicine, Vascular diseases, Medical equipment

The report also provides the compound annual growth rate (CAGR) for the global venous skin ulcer treatment market for the forecast period.

Key Points: 
  • The report also provides the compound annual growth rate (CAGR) for the global venous skin ulcer treatment market for the forecast period.
  • Analysts have employed a combination of top-down and bottom-up approach to study various phenomena in the global venous skin ulcer treatment market.
  • The report delves into the competition landscape of the global venous skin ulcer treatment market.Key players operating in the global venous skin ulcer treatment market have been identified, and each one of them has been profiled for their distinguishing business attributes.
  • Such valuable insights enable market stakeholders in making informed business decisions for investment in the global venous skin ulcer treatment market.

Spain: Biotech innovation - the EIB provides €20 million in financing to Sanifit to develop treatments for vascular calcification

Retrieved on: 
Friday, August 7, 2020
Biomineralization, Calcification, Calcium, Histopathology, Branches of biology, Natural sciences, Vascular diseases, Biology, RTT

To this end, the EU bank will provide a 20million loan to Spanish biopharmaceutical company Sanifit, which is developing novel treatments in two disease indications linked to calcification.

Key Points: 
  • To this end, the EU bank will provide a 20million loan to Spanish biopharmaceutical company Sanifit, which is developing novel treatments in two disease indications linked to calcification.
  • The EIB will provide Sanifit with long-term finance to drive the development of treatments for progressive vascular calcification disorders.
  • We are delighted to help a leading Spanish company to develop new medical treatments for vascular calcification that will have clear benefits for human health and wellbeing.
  • Sanifit is a clinical-stage biopharmaceutical company focused on treatments for vascular calcification disorders.

Tactile Medical to Present at the Canaccord Genuity 40th Annual Global Growth Conference

Retrieved on: 
Wednesday, August 5, 2020
Vascular diseases, Chronic venous insufficiency, Lymphedema, Canaccord Genuity, Venous insufficiency, Genuity, Chronic condition, Insufficiency, Medicine, Branches of biology

MINNEAPOLIS, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the Canaccord Genuity 40th Annual Global Growth Conference, which is being held virtually.

Key Points: 
  • MINNEAPOLIS, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the Canaccord Genuity 40th Annual Global Growth Conference, which is being held virtually.
  • Management will participate in a fireside chat on Wednesday, August 12th at 2:00 p.m. Eastern Time.
  • Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency.
  • Tactile Medicals Mission is to help people suffering from chronic diseases live better and care for themselves at home.